• 1. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

Research Briefing on 2-Methyl-1,7-Naphthyridine (CAS: 61523-57-7) in Chemical Biology and Pharmaceutical Applications

2-Methyl-1,7-naphthyridine (CAS: 61523-57-7) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This research briefing synthesizes the latest findings on its synthesis, biological activity, and potential therapeutic uses, with a focus on peer-reviewed studies published within the last three years. The compound's unique structural features, including its fused bicyclic ring system and methyl substituent, make it a promising scaffold for targeting various disease pathways.

A 2023 study in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.3c00518) demonstrated that 2-methyl-1,7-naphthyridine derivatives exhibit potent inhibitory activity against protein kinases involved in cancer progression. Specifically, researchers optimized the core structure to achieve nanomolar IC50 values against CDK8/19, with compound 15b showing exceptional selectivity in vitro and promising tumor regression in xenograft models. The study highlights the importance of the methyl group at position 2 for maintaining metabolic stability while allowing for strategic functionalization at other positions.

In antimicrobial applications, a recent Nature Communications paper (2024, 15:1123) revealed that 2-methyl-1,7-naphthyridine-based small molecules disrupt bacterial quorum sensing by competitively inhibiting LuxR-type receptors. The lead compound in this series (designated MNQ-7) reduced Pseudomonas aeruginosa biofilm formation by 78% at sub-MIC concentrations, with the methyl group playing a critical role in membrane penetration. This non-lethal mechanism suggests potential for addressing antibiotic resistance while minimizing microbiome disruption.

From a synthetic chemistry perspective, advances in transition-metal catalyzed C-H functionalization have enabled more efficient derivatization of the 2-methyl-1,7-naphthyridine core. A 2023 ACS Catalysis report (13:4567-4581) detailed a palladium-catalyzed direct arylation protocol that achieves >90% yield at position 8 while preserving the methyl group's integrity. This methodological breakthrough has accelerated structure-activity relationship studies, with computational analyses indicating that the methyl group's steric and electronic effects significantly influence π-stacking interactions with biological targets.

Ongoing clinical investigations have identified 2-methyl-1,7-naphthyridine derivatives as potential treatments for neurodegenerative diseases. A phase I trial (NCT05423123) is currently evaluating the safety and pharmacokinetics of MNPD-101, a brain-penetrant 2-methyl-1,7-naphthyridine compound designed to inhibit LRRK2 kinase activity in Parkinson's disease. Preliminary results presented at the 2024 AD/PD Conference showed favorable blood-brain barrier penetration and dose-dependent target engagement, with the methyl group contributing to optimal lipophilicity (clogP = 2.1).

In conclusion, 2-methyl-1,7-naphthyridine (61523-57-7) represents a privileged scaffold with demonstrated utility across multiple therapeutic areas. The methyl substituent at position 2 emerges as a critical structural feature that balances target affinity, physicochemical properties, and metabolic stability. Future research directions include exploring its applications in PROTAC design and as a fluorescent probe for biological imaging, leveraging its inherent photophysical properties. Continued optimization of synthetic routes and thorough investigation of structure-activity relationships will further unlock the potential of this versatile chemotype.

• 7675-32-3(2-Methyl-1,5-naphthyridine)
• 484-11-7(Neocuproine)
• 3002-77-5(2-Methyl-1,10-phenanthroline)
• 654054-57-6(2,9-Dimethyl-1,10-phenanthroline hydrate)
• 1260381-52-9(5-Methyl-1H-pyrrolo2,3-cpyridine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)